Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

5:11 PM ET 8-K
Licensing Deal Evommune, Inc. EVMN

Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M

Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.

Value
$30M
Counterparty
Hinova Pharmaceuticals Inc.
Term
Royalty Term
5:10 PM ET 8-K
M&A Deal Novagold Resources Inc NG

Novagold Resources M&A Deal with Paulson Advisers LLC

NOVAGOLD shareholders approved a transaction to consolidate 100% ownership of the Donlin Gold project by acquiring the 40% interest held by Paulson Advisers LLC. The all-share transaction involves the creation of a new Delaware parent company, New NOVAGOLD, which will acquire all outstanding NOVAGOLD shares and the Donlin Gold interests in exchange for new voting and non-voting stock.

Counterparty
Paulson Advisers LLC
5:06 PM ET 8-K
M&A Deal Kimberly Clark Corp KMB

Kimberly Clark Signs $7B M&A Deal with Kenvue Inc.

Kimberly-Clark Corporation completed its acquisition of Kenvue Inc. through a two-step merger process, resulting in Kenvue becoming a wholly owned subsidiary renamed Kenvue LLC. In connection with the closing, Kimberly-Clark assumed $7 billion in aggregate principal amount of Kenvue's senior notes and launched exchange offers to swap them for new Kimberly-Clark notes.

Value
$7B
Counterparty
Kenvue Inc.
5:03 PM ET 8-K
Capital Raise FTC Solar, Inc. FTCI

FTC Solar Capital Raise

FTC Solar, Inc. announced it has resumed the use of its at-the-market (ATM) offering program and executed sales of common stock on November 4, 2026. This decision reverses a previous statement from its Q3 2026 report where the company indicated it had no current plans to utilize the remaining capacity. Future sales under the program will depend on market conditions and other factors.

Counterparty
H.C. Wainwright & Co., LLC
4:51 PM ET 8-K/A
M&A Deal Martin Marietta Materials Inc MLM

Martin Marietta Materials Signs $12.9B M&A Deal with Lhoist North America, Inc.

Martin Marietta Materials completed the acquisition of Lhoist North America (LNA) for a total consideration of $12.887 billion. The deal was funded through $7.028 billion in cash and the issuance of approximately 10.95 million shares of common stock. This filing provides updated pro forma financial information reflecting the impact of the acquisition and related debt financing.

Value
$12.9B
Counterparty
Lhoist North America, Inc.
4:51 PM ET 8-K
Capital Raise Oracle Corp ORCL

Oracle Capital Raise of $10B

Oracle Corporation completed a massive $10 billion common stock offering, issuing 86,206,897 shares to raise capital. Simultaneously, the company closed a separate $10 billion debt offering across five tranches of senior notes with maturities ranging from 2029 to 2046. These combined $20 billion capital markets transactions represent a significant liquidity event for the enterprise.

Value
$10B
Counterparty
BofA Securities, Inc.
4:48 PM ET 8-K
Capacity Expansion Vivakor, Inc. VIVK

Vivakor Capacity Expansion

Vivakor announced the receipt of a nonbinding letter of intent to lease 12.9 acres at a major Texas international airport for the development of a hydrogen production plant and fueling station. The project is planned in phases, starting with fueling infrastructure for hydrogen-powered buses and CNG vehicles, followed by an on-site hydrogen production plant using airport-generated organic waste as feedstock.

4:37 PM ET 8-K
Capital Raise Beneficient BENF

Beneficient Capital Raise

Beneficient shareholders approved the issuance of Class A Common Stock to YA II PN, Ltd. (Yorkville) under an Amended and Restated Standby Equity Purchase Agreement (A&R SEPA). The approval satisfies Nasdaq Listing Rule 5635(d), allowing the company to issue shares representing more than 20% of its outstanding common stock upon the conversion of $4.0 million in promissory notes.

Counterparty
YA II PN, Ltd.
4:32 PM ET 8-K
Capital Raise OpenWorld, Inc. OPNW

OpenWorld Capital Raise

Stockholders holding 50.27% of OpenWorld's voting power approved the issuance of up to 5,035,970 shares of common stock upon the exercise of Series A and Series B warrants. The approval, conducted via written consent, satisfies Nasdaq Listing Rule 5635(d) requirements related to a registered direct offering previously announced on October 30, 2026.

4:32 PM ET 8-K
Capital Raise Cohen & Steers Income Opportunities REIT, Inc. CNSREIT

Cohen & Steers Income Opportunities REIT Capital Raise of $8.27M

Cohen & Steers Income Opportunities REIT, Inc. issued multiple classes of common shares in an unregistered private placement on November 2, 2026. The company sold a total of 668,042 shares across Class P, B, R-I, R-S, and M-I for aggregate consideration of approximately $8.27 million. The offering was conducted under Section 4(a)(2) and Regulation D exemptions.

Value
$8.27M
4:32 PM ET 8-K
Capital Raise Blackstone Real Estate Income Trust, Inc. BSTT

Blackstone Real Estate Income Trust Capital Raise of $23.4M

Blackstone Real Estate Income Trust, Inc. sold approximately $23.4 million of unregistered Class S-2 common stock in a continuous private offering to accredited investors. The shares were priced at the company's net asset value per share as of September 30, 2026, plus applicable upfront selling commissions.

Value
$23.4M
4:32 PM ET 8-K
Clinical Trial Data Citius Pharmaceuticals, Inc. CTXR

Citius Pharmaceuticals Clinical Trial Data

Citius Pharmaceuticals' subsidiary, Citius Oncology, presented health-related quality of life (HRQoL) data from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. The data showed that patients who responded to the treatment reported sustained improvements in skin-related quality of life measures and significant reductions in pruritus (itching).

Counterparty
European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG)
4:32 PM ET 8-K
Clinical Trial Data Citius Oncology, Inc. CTOR

Citius Oncology Clinical Trial Data

Citius Oncology announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. Data presented at the EORTC-CLTG 2026 Annual Meeting showed that patients who responded to treatment reported sustained improvements in skin-related quality of life and significant reductions in pruritus (itching).

4:31 PM ET 8-K
Capital Raise XMax Inc. XMAX

XMax Capital Raise

XMax Inc. shareholders approved several proposals at a special meeting, including the ratification of previous stock issuances and the approval of new equity offerings. Specifically, shareholders authorized the issuance of more than 20% of the company's common stock in both a private placement and a registered direct shelf offering at prices below the Nasdaq minimum price requirement.

4:21 PM ET 8-K
M&A Deal Ingram Micro Holding Corp INGM

Ingram Micro Holding M&A Deal with Ingram Holdco, LLC

Ingram Micro Holding Corp's principal stockholder, Ingram Holdco, LLC (an affiliate of Platinum Equity), sold 12,650,000 shares of common stock in a secondary offering, including the full exercise of the underwriter's overallotment option. The company received no proceeds from the sale but concurrently repurchased 1,000,000 shares from the underwriter as part of its existing $175 million stock repurchase program.

Counterparty
Ingram Holdco, LLC
4:21 PM ET 8-K
M&A Deal Bowman Consulting Group Ltd. BWMN

Bowman Consulting Group M&A Deal with Bernhard Capital Partners

Bowman Consulting Group Ltd. shareholders approved the company's acquisition by Prive Parent, Inc., an affiliate of Bernhard Capital Partners. Approximately 84% of outstanding shares were represented at the special meeting, with the merger proposal receiving overwhelming support. The transaction will result in Bowman becoming a wholly owned subsidiary of Parent, subject to remaining customary closing conditions.

Counterparty
Bernhard Capital Partners
4:17 PM ET 8-K
M&A Deal Non Invasive Monitoring Systems Inc NIMU

Non Invasive Monitoring Systems M&A Deal with Gravitics, Inc.

Non-Invasive Monitoring Systems, Inc. entered into a fifth amendment to its merger agreement with Gravitics, Inc., extending the outside closing and termination date from October 30, 2026, to November 30, 2026. Additionally, the company extended the maturity dates for several affiliate promissory notes and a $0.81 million convertible note to align with the new merger timeline.

Counterparty
Gravitics, Inc.
4:16 PM ET 8-K
Nasdaq/NYSE Compliance Notice Borealis Foods Inc. BRLS

Borealis Foods Nasdaq/NYSE Compliance Notice

Borealis Foods notified Nasdaq that it was briefly out of compliance with Listing Rule 5605(c)(2)(A) because its Audit Committee fell below the required three members following a director's committee resignation. The company regained compliance on October 29, 2026, by appointing Danat Shiderkulov to the Board and its committees, filling vacancies left by the resignation of Pavel Mynzhanov and the committee departures of Zaure Algaziyeva.

Counterparty
Nasdaq
4:15 PM ET 8-K
M&A Deal Carlyle Credit Solutions

Carlyle Credit Solutions M&A Deal with Carlyle Credit Solutions, Inc.

Carlyle Credit Solutions completed its reorganization from a Maryland corporation into a Delaware statutory trust. As part of the transaction, the successor fund entered into new investment advisory and administration agreements with Carlyle Global Credit Investment Management and Carlyle Global Credit Administration.

Counterparty
Carlyle Credit Solutions, Inc.
4:14 PM ET 8-K
Capacity Expansion Freeport-Mcmoran Inc FCX

Freeport-Mcmoran Capacity Expansion: $4.5B Investment

Freeport-McMoRan's Board of Directors approved a $4.5 billion expansion and modernization program for its Bagdad copper and molybdenum operation in Arizona. The project will more than double mining and milling rates, positioning Bagdad as the second-largest copper mine in the U.S. and a leading molybdenum producer.

Value
$4.5B
Term
2027-2030

“Freeport’s significant resource base provides an attractive portfolio of value-enhancing, organic growth options as we work to meet growing demand for our products. We are pleased to proceed with the Bagdad expansion, an important step in advancing Freeport’s U.S. copper growth strategy. This low-risk brownfield project builds on Bagdad’s substantial reserve base, long operating history, existing infrastructure and experienced workforce to deliver new U.S. copper and molybdenum production and further strengthen Freeport’s position as America’s Copper Champion®.”

Kathleen Quirk, President and Chief Executive Officer
4:07 PM ET 8-K
Capital Raise Nordicus Partners Corp NORD

Nordicus Partners Capital Raise

Nordicus Partners Corp closed a private offering of 40,000 restricted shares of common stock to two private investors. The shares were issued at a price of $2.00 per share, resulting in total proceeds of $80,000. The transaction was conducted as a private placement exempt from registration under Section 4(a)(2) and Regulation D.

4:02 PM ET 8-K
Capital Raise Apollo IG Core Replacement, L.P.

Apollo IG Core Replacement Capital Raise of $479M

Apollo IG Core Replacement, L.P. issued unregistered limited partnership interests for aggregate cash consideration of approximately $478.8 million on November 1, 2026. The sale was conducted as part of the company's continuous private offering. Additionally, the company reported a Net Asset Value (NAV) of $1,295.5 million as of September 30, 2026.

Value
$479M
4:02 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.

4:02 PM ET 8-K
Clinical Trial Data ADC Therapeutics SA ADCT

ADC Therapeutics Clinical Trial Data

ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.

4:01 PM ET 8-K
M&A Deal Neogen Corp NEOG

Neogen M&A Deal with Zoetis Inc.

Neogen Corporation provided a status update on the pending sale of its global Genomics business to Zoetis Inc. To facilitate regulatory clearance from the ACCC and NZCC, Zoetis has offered to divest certain assets in Australia, with the transaction now expected to close in early 2027.

Counterparty
Zoetis Inc.
4:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Bayview Acquisition Corp BAYA

Bayview Acquisition Nasdaq/NYSE Compliance Notice

Bayview Acquisition Corp received notice that the Nasdaq board of directors declined to review a prior decision to delist the company's securities. Nasdaq will proceed with filing a Form 25-NSE to formally remove the company's units, ordinary shares, and rights from listing. The company is currently seeking to have its ordinary shares quoted on the OTC Pink Market.

Counterparty
Nasdaq
4:00 PM ET 8-K
Capital Raise New Mountain Net Lease Trust NEWLEASE

New Mountain Net Lease Trust Capital Raise of $31.1M

New Mountain Net Lease Trust sold 1,476,784 common shares in a continuous private offering for approximately $31.13 million. The sale included Class F and Class I common shares issued at the most recently determined net asset value per share.

Value
$31.1M
4:00 PM ET 8-K
Capital Raise Jefferies Credit Partners BDC Inc.

Jefferies Credit Partners BDC Capital Raise of $6.61M

Jefferies Credit Partners BDC Inc. sold 462,715.212 unregistered shares of its Class I common stock to third-party investors. The shares were sold at a price of $14.29202 per share, representing the company's NAV as of September 30, 2026, for total consideration of approximately $6.61 million.

Value
$6.61M
3:45 PM ET 8-K
Capital Raise Narragansett Bancorp, Inc. NARA

Narragansett Bancorp Capital Raise of $91M

Narragansett Bancorp, Inc. completed its initial public offering and two-tier holding company reorganization for BayCoast Bank on November 2, 2026. The company sold 9,098,800 shares of common stock at the adjusted maximum of its offering range, with shares beginning trade on the Nasdaq Capital Market under the symbol 'NARA'.

Value
$91M
3:42 PM ET 8-K
Capital Raise Willow Tree Capital Corp

Willow Tree Capital Capital Raise of $1.1M

Willow Tree Capital Corporation sold approximately 67,131 shares of common stock in a private placement for an aggregate offering price of $1.1 million. The shares were sold at a price of $15.97 per share pursuant to subscription agreements with investors under Regulation D exemptions.

Value
$1.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.